


error. Attached hereto is a marked-up version of the changes made to the specification and claim 84 by the current amendment. The attached page(s) are captioned **"VERSION WITH MARKINGS TO SHOW CHANGES MADE."**

Early consideration and allowance of claims 1-56 and 58-85 are respectfully requested.

In the event any additional fees are due, please charge our Deposit Account No. 22-0256.

Respectfully submitted,  
VARNDELL & VARNDELL, PLLC  
(formerly Varndell Legal Group)



R. Eugene Varndell, Jr.  
Registration No. 29,728

Atty. Case No. VX012273 PCT  
106-A South Columbus Street  
Alexandria, Virginia 22314  
(703) 683-9730  
V:\VDOCS\W\_DOCS\NOV01\P080-2273 PCT 2PA.DOC

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

The paragraph that begins on page 20, line 2, was rewritten as follows:

-- Endoglucanase RCE II of the invention is an enzyme having the amino acid sequence spanning from position 1 to position 343 of SEQ ID NO: 3 and having endoglucanase activity. The amino acid sequence spanning from position -23 to position -1 of SEQ ID NO: [1] 3 or a part thereof may be added to the N-terminus of the above protein. The polypeptide to which this sequence is added is included within the invention as a modified peptide of endoglucanase RCE II. Since this amino acid sequence spanning from position -23 to position -1 is believed to be a signal peptide, a part of the sequence means a partial sequence retaining the signal peptide activity as well as a sequence remaining at the N-terminus as a result of some difference that occurred in the site of processing depending on the type of the host. --

The paragraph that begins on page 20, line 20, was rewritten as follows:

-- Endoglucanase RCE III of the invention is an enzyme having the amino acid sequence spanning from position 1 to position 337 of SEQ ID NO: 5 and having endoglucanase activity. The amino acid sequence spanning from position -23 to position -1 of SEQ ID NO: [1] 5 or a part thereof may be added to the N-terminus of the above protein. The polypeptide to which this sequence is added is included within the invention as a modified peptide of endoglucanase RCE III.

Since this amino acid sequence spanning from position -23 to position -1 is believed to be a signal peptide, a part of the sequence means a partial sequence retaining the signal peptide activity as well as a sequence remaining at the N-terminus as a result of some difference that occurred in the site of processing depending on the type of the host. --

The paragraph that begins on page 45, line 5 from the bottom of the page, was rewritten as follows:

-- To express RCE I gene in yeast, the following investigations were done using the host-vector system as described in [WO97/00757] WO97/34004 specification. --

The paragraph that begins on page 51, last line, was rewritten as follows:

-- Expression of RCE II gene in yeast was carried out according to the method of Example B7 (2). Thus, the plasmid pRCEII-Bgl obtained in Example C4 (1) was digested with BglII and the endoglucanase RCE II gene was recovered. This gene was operably ligated into BamHI site, i.e., downstream from glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter, of plasmid vector pY2831 to yield a plasmid pYRCEII. This plasmid was used to transform yeast (*Saccharomyces cerevisiae*) strain MS-161 (MATa, trp1, ura3) according to [WO97/00757] WO97/34004 specification to yield a transformant in which the endoglucanase RCE II was capable of expression. --

The paragraph that begins on page 77, line 9 from the bottom of the page, was rewritten as follows:

-- The mutant RCE I gene was expressed in yeast according to the method of Example B7 (2). Thus, the plasmid pMCEI-G obtained in Example E3 (1) was digested with EcoRI and a mutant MCE I gene was recovered. This gene was operably linked to the EcoRI site downstream from glyceraldehyde-3-phosphate dehydrogenase (GAP) promoter of plasmid vector pY2831 to yield a plasmid pYMCEI. This plasmid was used to transform yeast (*Saccharomyces cerevisiae*) strain MS-161 (MATa, trp1, ura3) according to [WO97/00757] WO97/34004 specification. Thus, a transformant was obtained in which the endoglucanase MCE I could be expressed. --

IN THE CLAIMS:

Claim 84 was amended as follows:

-- 84. (Twice Amended) A method of deinking a waste paper, comprising a step of treating the waste paper where the [endoglucanase] enzyme, protein, modified protein or homologue according to claim 1 in the presence of a deinking agent. --